Drugs / Human Serum Albumin/interferon alpha2a Fusion Protein
Human Serum Albumin/interferon alpha2a Fusion Protein
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01901198 | Apr → Sep 2013 | — | Beijing Bio-Fortune Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Serum Albumin/interferon alpha2a Fusion Protein | “This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein single dose in Chinese...” NCT01901198 ↗ |
| Known as | Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein | “This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein single dose in Chinese...” NCT01901198 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein” NCT01901198 ↗ |
| Route | Subcutaneous | “Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.” NCT01901198 ↗ |